A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Amano K, Takedani H, Tamashima S, Matsushita T, Tawa A, Tanaka I, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Kawakami K, Ohashi Y, Saito H.
Shirahata A, et al. Among authors: takamatsu j.
Haemophilia. 2013 Nov;19(6):853-60. doi: 10.1111/hae.12205. Epub 2013 Jun 6.
Haemophilia. 2013.
PMID: 23738888
Clinical Trial.